Impact of extremely low-frequency electromagnetic field (100 Hz, 100 G) exposure on human glioblastoma U87 cells during Temozolomide administration

• Published in: Electromagnetic biology and medicine Vol. 38; no. 3; pp. 198 - 209
• Main Authors: Ahmadi-Zeidabadi, Meysam, Akbarnejad, Zeinab, Esmaeeli, Marzie, Masoumi-Ardakani, Yaser, Mohammadipoor-Ghasemabad, Lily, Eskandary, Hossein
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 03.07.2019
• Subjects: Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Apoptosis - radiation effects; Calcium - metabolism; cancer; Carcinogenesis - drug effects; Carcinogenesis - radiation effects; Cell Differentiation - drug effects; Cell Differentiation - radiation effects; Cell Line, Tumor; Cell Survival - drug effects; Cell Survival - radiation effects; differentiation; Drug Resistance, Neoplasm - radiation effects; Electromagnetic field; Electromagnetic Fields; Gene Expression Regulation, Neoplastic - drug effects; Gene Expression Regulation, Neoplastic - radiation effects; glioblastoma; Glioblastoma - pathology; Humans; Lipid Peroxidation - drug effects; Lipid Peroxidation - radiation effects; Superoxide Dismutase - metabolism; Temozolomide; Temozolomide - administration & dosage; Temozolomide - pharmacology; Electromagnetic field; cancer; differentiation; glioblastoma; Temozolomide

Glioblastoma multiforme (GBM) is a highly malignant brain tumor with an extremely dismal prognosis, a median survival is12 months. Temozolomide (TMZ) is an alkylating agent widely used to treat cancer, resistance to this drug is often found. One unexplored possibility for overcoming this resistance...